Neutralising antibodies targeting PDPN showed inhibition of tumour growth and metastasis in xenograft models for osteosarcoma, oral cancer, and malignant pleural mesothelioma (MPM) [313–315], supporting clinical assessment of anti-PDPN antibodies in the future. This evidence concerns the gene PDPN and lip and oral cavity carcinoma.